Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$13.86 +1.1%	$11.03	$7.19 ▼ $14.85	$54.45B	0.59	1.34 million shs	569,005 shs
REGN Regeneron Pharmaceuticals	$626.36 +0.5%	$658.68	$529.69 ▼ $821.11	$66.11B	0.25	867,839 shs	669,477 shs
TAK Takeda Pharmaceutical	$15.94 -0.6%	$16.13	$12.99 ▼ $18.90	$50.68B	-0.08	3.02 million shs	1.47 million shs
ZTS Zoetis	$72.93 +1.5%	$86.77	$71.47 ▼ $161.77	$30.60B	0.75	5.63 million shs	3.36 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	+4.82%	+25.23%	+29.86%	+18.10%	+81.70%
REGN Regeneron Pharmaceuticals	-1.31%	+0.89%	+1.42%	-19.78%	+18.77%
TAK Takeda Pharmaceutical	+0.31%	+1.17%	+0.31%	-14.65%	+3.59%
ZTS Zoetis	-1.73%	-6.47%	-7.62%	-38.80%	-53.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$13.86 +1.1%	$11.03	$7.19 ▼ $14.85	$54.45B	0.59	1.34 million shs	569,005 shs
REGN Regeneron Pharmaceuticals	$626.36 +0.5%	$658.68	$529.69 ▼ $821.11	$66.11B	0.25	867,839 shs	669,477 shs
TAK Takeda Pharmaceutical	$15.94 -0.6%	$16.13	$12.99 ▼ $18.90	$50.68B	-0.08	3.02 million shs	1.47 million shs
ZTS Zoetis	$72.93 +1.5%	$86.77	$71.47 ▼ $161.77	$30.60B	0.75	5.63 million shs	3.36 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	+4.82%	+25.23%	+29.86%	+18.10%	+81.70%
REGN Regeneron Pharmaceuticals	-1.31%	+0.89%	+1.42%	-19.78%	+18.77%
TAK Takeda Pharmaceutical	+0.31%	+1.17%	+0.31%	-14.65%	+3.59%
ZTS Zoetis	-1.73%	-6.47%	-7.62%	-38.80%	-53.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	2.86	Moderate Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.73	Moderate Buy	$792.65	26.27% Upside
TAK Takeda Pharmaceutical	2.25	Hold	N/A	N/A
ZTS Zoetis	2.38	Hold	$126.92	71.75% Upside

Current Analyst Ratings Breakdown

Latest REGN, BAYRY, ZTS, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2026	ZTS Zoetis	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$136.00 ➝ $85.00
6/30/2026	ZTS Zoetis	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$150.00 ➝ $104.00
6/29/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/26/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$95.00 ➝ $85.00
6/24/2026	REGN Regeneron Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
6/23/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
6/12/2026	ZTS Zoetis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
5/29/2026	BAYRY Bayer Aktiengesellschaft	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
5/27/2026	ZTS Zoetis	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/22/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$105.00 ➝ $95.00
5/19/2026	BAYRY Bayer Aktiengesellschaft	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	1.06	$2.31 per share	5.99	$7.50 per share	1.85
REGN Regeneron Pharmaceuticals	$14.34B	4.63	$41.71 per share	15.05	$295.66 per share	2.12
TAK Takeda Pharmaceutical	$28.32B	1.79	$3.10 per share	5.15	$15.41 per share	1.04
ZTS Zoetis	$9.47B	3.27	$7.63 per share	9.68	$7.56 per share	9.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$4.10B	-$0.64	N/A	10.50	4.17	-4.75%	17.61%	4.81%	8/4/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	15.30	15.05	1.39	29.65%	13.16%	10.17%	7/30/2026 (Estimated)
TAK Takeda Pharmaceutical	-$1.01B	$0.39	40.91	13.09	N/A	4.31%	11.20%	5.48%	7/30/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.03	12.26	10.03	1.14	27.80%	66.85%	18.79%	8/6/2026 (Estimated)

Latest REGN, BAYRY, ZTS, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2026	Q1 2026	BAYRY Bayer Aktiengesellschaft	$0.64	$0.79	+$0.15	$0.82	$15.77 billion	$15.73 billion
5/7/2026	Q1 2026	ZTS Zoetis	$1.60	$1.53	-$0.07	$1.42	$2.30 billion	$2.26 billion
4/29/2026	Q1 2026	REGN Regeneron Pharmaceuticals	$8.91	$9.47	+$0.56	$6.75	$3.48 billion	$3.61 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.15%	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.60%	N/A	9.16%	N/A
TAK Takeda Pharmaceutical	$0.48	3.00%	-18.61%	123.08%	N/A
ZTS Zoetis	$2.12	2.95%	+20.11%	35.16%	14 Years

Latest ZTS, REGN, BAYRY, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2026	ZTS Zoetis	quarterly	$0.53	2.66%	7/20/2026	7/20/2026	9/1/2026
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.58%	5/20/2026	5/20/2026	6/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.06	1.05	0.70
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96
TAK Takeda Pharmaceutical	0.59	1.09	0.60
ZTS Zoetis	2.80	3.15	1.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	83.31%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	6.97%
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	88,078	3.93 billion	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	14,500	419.23 million	418.31 million	Optionable

TAK, BAYRY, REGN, and ZTS Headlines

Recent News About These Companies

Branded pharmaceuticals stocks Q1 teardown: Zoetis (NYSE:ZTS) vs the rest

July 1 at 9:38 AM | msn.com

This analyst thinks stabilization for Zoetis’ products could be several quarters away

July 1 at 9:38 AM | msn.com

ZOETIS INC. INVESTORS WITH LOSSES HAVE UNTIL JULY 27, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 1 at 9:34 AM | globenewswire.com

Barclays Lowers Zoetis (NYSE:ZTS) Price Target to $85.00

July 1 at 8:05 AM | marketbeat.com

Janney Montgomery Scott LLC Has $18.47 Million Holdings in Zoetis Inc. $ZTS

July 1 at 4:48 AM | marketbeat.com

Zoetis (ZTS) share price

June 30 at 11:55 PM | economictimes.indiatimes.com

Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

June 30 at 6:57 PM | prnewswire.com

ZTS FINAL DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

June 30 at 4:32 PM | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS

June 30 at 4:32 PM | globenewswire.com

Lansforsakringar Fondforvaltning AB publ Buys 64,921 Shares of Zoetis Inc. $ZTS

June 30 at 5:27 AM | marketbeat.com

21,500 Shares in Zoetis Inc. $ZTS Bought by Louisiana State Employees Retirement System

June 30 at 4:55 AM | marketbeat.com

Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors that a Class Action Lawsuit Has Been Filed Against Zoetis and Encourages Investors to Contact the Firm Before the July 27th Deadline

June 29 at 5:48 PM | globenewswire.com

ZOETIS DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

June 29 at 2:37 PM | newsfilecorp.comN

Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS

June 29 at 2:08 PM | globenewswire.com

Deadline Alert: Zoetis Inc. (ZTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

June 29 at 1:06 PM | globenewswire.com

Why Is Zoetis (NYSE:ZTS) Turning Heads Today?

June 29 at 12:45 PM | kalkinemedia.comK

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

June 29 at 12:00 PM | newsfilecorp.comN

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

June 29 at 4:32 AM | prnewswire.com

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 29 at 4:30 AM | prnewswire.com

ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

June 28 at 8:41 PM | globenewswire.com

Pictet Asset Management Holding SA Has $227.45 Million Holdings in Zoetis Inc. $ZTS

June 28 at 5:35 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TAK, BAYRY, REGN, and ZTS Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$13.86 +0.16 (+1.13%)

As of 03:11 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Regeneron Pharmaceuticals NASDAQ:REGN

$626.36 +2.82 (+0.45%)

As of 03:29 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Takeda Pharmaceutical NYSE:TAK

$15.94 -0.10 (-0.59%)

As of 03:29 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$72.93 +1.07 (+1.49%)

As of 03:29 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REGN, BAYRY, ZTS, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REGN, BAYRY, ZTS, and TAK Earnings

Compare Dividends

Latest ZTS, REGN, BAYRY, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TAK, BAYRY, REGN, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TAK, BAYRY, REGN, and ZTS Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Regeneron Pharmaceuticals NASDAQ:REGN

Takeda Pharmaceutical NYSE:TAK

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools